Introduction
============

Immunoglobulin A nephropathy (IgAN) is a type of glomerular disorder, which is an important cause of kidney failure ([@b1-mmr-17-05-7027]). Patients usually present macroscopic hematuria during a gastrointestinal or upper respiratory infection ([@b2-mmr-17-05-7027]). However, the diagnosis of IgAN requires kidney biopsy, which may lead to various complications ([@b3-mmr-17-05-7027],[@b4-mmr-17-05-7027]). Although IgAN is increasingly considered to be a systemic immune complex deposition disorder, the kidney is most commonly affected, and damage may frequently recur even subsequent to kidney transplantation ([@b5-mmr-17-05-7027]). Deposited immune complexes contain a number of classes of antibody, although IgA1 is the most frequent and is often the dominant or co-dominant class. Certain autoreactive IgA1 antibodies that are specific for the hinge region of IgA1 have additionally been observed in serum from patients with IgAN ([@b6-mmr-17-05-7027]). Although the trigger of autoantibodies and formation of immune complexes has remained unclear until now, certain studies have indicated that susceptibility alleles in the antigen region of leukocytes and adaptive immunity may serve key roles in the pathogenesis of IgAN ([@b7-mmr-17-05-7027],[@b8-mmr-17-05-7027]).

Human adaptive immunity is mediated by leukocytes, including B and T cells, which have been demonstrated to be selectively activated by interactions between antigens and their receptors expressed on the surface of lymphocytes ([@b9-mmr-17-05-7027]). Therefore, understanding the spectrum of antigen receptors present on B and T cells, known as the immune repertoire, may aid in identifying biomarkers and the development of therapeutics for IgAN ([@b10-mmr-17-05-7027]). In the antigen-binding site of B-cell receptors (BCRs)/T-cell receptors (TCRs), specific recognition of countless diverse peptide-major histocompatibility complexes are determined by three complementarity-determining regions (CDRs): CDR1, CDR2 and CDR3. Studies have indicated that CDR1 and CDR2 are relatively conserved and are encoded by different germline DNA sequences; however, CDR3 is encoded by genomic loci that undergo somatic recombination of VDJ gene segments and are assembled into highly diverse junctional residues ([@b11-mmr-17-05-7027],[@b12-mmr-17-05-7027]). Therefore, the DNA sequences encoding CDR3 in the BCR/TCR could provide structural information about primary receptor antigenic binding sites. In the literature, few studies have focused on the diversity of the TCR at the nucleotide sequence level in IgAN. In a study by Wu *et al* ([@b13-mmr-17-05-7027]), 14 patients with IgAN were divided into a stable and a progressive group, and TCR CDR3 sequences were cloned and analyzed by the dideoxy chain determination method. The results revealed that certain conserved amino acids in the TCR CDR3 contributed to the recognition of a particular antigen or set of antigens. However, as the human immune repertoire includes B and T cells, TCR CDR3 is only part of the information. In another study, TCR diversity in IgAN was assessed using traditional techniques, included targeted cloning and Sanger sequencing, which are low-throughput methods and allowed for only a descriptive assessment of 20 TCR Vβ families ([@b14-mmr-17-05-7027]). In the present study, a comprehensive analysis of BCR/TCR CDR3 diversity was attempted, in order to provide novel information about IgAN by multiplex PCR, high-throughput sequencing and bioinformatics.

Materials and methods
=====================

### Study subjects

Written informed consent was obtained from each participant. The study was approved by the Ethics Committee of Shenzhen People\'s Hospital and abided by the ethical principles of the Helsinki Declaration of 1975, as revised in 2000. Peripheral blood samples with fresh EDTA-K2 anticoagulant were obtained from eight South Chinese patients with IgAN and six South Chinese healthy controls in Shenzhen People\'s Hospital, China. Samples were collected at the time of the initial diagnosis of IgAN and prior to drug treatments. The renal biopsies were performed under direct ultrasound guidance with automated biopsy needles; the sections of biopsy tissues were stained by periodic acid-Schiff stain at 20°C for 10 min, and the mesangial IgA deposition was confirmed by immunofluorescence using fluorescein isothiocyanate-labelled IgA antibodies (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) ([@b15-mmr-17-05-7027]). The diagnosis of IgAN was confirmed by clinical and biopsy findings ([Fig. 1](#f1-mmr-17-05-7027){ref-type="fig"}), which were according to the Lee glomerular grading system ([@b16-mmr-17-05-7027]). Of the 8 patients with IgAN, 5 were female and 3 were male, and the mean age was 34.6±6.63 years (range, 26--45 years; [Table I](#tI-mmr-17-05-7027){ref-type="table"}). The six healthy controls were healthy volunteers, 2 men and 4 women, and the mean age was 34.0±6.3 years (range, 27--45 years), and they were matched to the patients in terms of sex, age and ethnicity.

### Cell sub-population isolation and DNA extraction

Peripheral blood mononuclear cells (PBMCs) were isolated from each peripheral blood sample using LymphoPrep (Axis Shield Diagnostics Ltd., Dundee, UK), according to the manufacturer\'s protocol. For the isolation of B cells, the non-B cells of each PBMC sample were depleted using MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) using a MACS Separator (Miltenyi Biotec GmbH). The T cells were isolated from each PBMC sample using CD3 MicroBeads (Miltenyi Biotec GmbH), according to the manufacturer\'s protocol. DNA was extracted from the isolated B and T cells using a QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s protocol.

### Preparation of BCR/TCR libraries by multiplex-polymerase chain reaction (PCR)

The human DNA sequences of BCR/TCR CDR3, which are the most diverse DNA sequences, were obtained from IMGT ([www.imgt.org](www.imgt.org)). The relatively conserved regions in the BCR/TCR DNA sequences were designed as the primer combining sites, and amplification by multiplex-PCR was performed according to previous studies, with minor modifications ([@b17-mmr-17-05-7027],[@b18-mmr-17-05-7027]). Briefly, equal amounts of DNA taken from each sample were used to construct a library, with primers covering the majority of the V, D and J gene families, including 16 primers to amplify BCR CDR3 ([Table II](#tII-mmr-17-05-7027){ref-type="table"}), and 44 primers to amplify TCR CDR3 ([Table III](#tIII-mmr-17-05-7027){ref-type="table"}). The multiplex-PCR was performed using a QIAGEN Multiplex PCR kit. For the amplification of BCR CDR3, the PCR mixture was amplified under the following conditions: 95°C (15 min) followed by 25 cycles of 94°C (15 sec), 60°C (3 min) and 72°C (10 min) For the amplification of TCR CDR3, the PCR mixture was amplified under the following conditions: 95°C (15 min), followed by 30 cycles of 94°C (15 sec), 59°C (30 sec) and 72°C (11 min). The PCR products were purified using a QIA quick PCR Purification kit (Qiagen GmbH) and AMPure XP beads (Beckman Coulter, Inc., Brea, CA, USA). The sequencing index was added to each PCR product sample, and the quantity of each library was analyzed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.) quantitative PCR using the KAPA Library Quantification kit, following manufacturer\'s protocol (Kapa Biosystems, Inc., Wilmington, MA, USA), as previously described ([@b19-mmr-17-05-7027]).

### Deep sequencing and data analysis

The libraries were sequenced using Hiseq 2000 following the manufacturer\'s protocol (Illumina, Inc., San Diego, CA, USA). In order to control the sequencing quality, internal controls consisting of defined DNA fragments were used in the sequence detection. The defined DNA fragments ranged between 170 and 800 bp, and enabled the estimation of error rates (E). The quality scores of sequencing (sQ), which were one important criterion for read filtering, ranged from 0 to 40, and the relationship between sQ and E was calculated by the following formula:
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In order to obtain clean immune sequences, the adapters and the reads with sQ \<15 or N bases \>5% in the raw data generated by Hiseq 2,000, were filtered, as previously described ([@b17-mmr-17-05-7027]). The clean data were expected to have sequence lengths of \>60 nucleotides; and the pair-end read pairs, which had identity-aligning tail regions or sequences with 90% matched bases (≥10 bp overlapping), were merged into a single-contig sequence using COPE v1.1.3 and FqMerger (both BGI, Shenzhen, China). Following low-quality read filtering, the clean data were used in further alignments with the online tool IMGT/HighV-QUEST ([@b20-mmr-17-05-7027]). The web portal of IMGT^®^ and the international ImMunoGeneTics information system^®^ ([www.imgt.org](www.imgt.org)) was used to analyze the nucleotide sequence rearrangement of BCRs/TCRs obtained from high-throughput sequencing. The output data included each distinct DNA sequence of BCR/TCR, IMGT clonotypes (AA), VDJ gene assignment and distribution of CDR3 length. Statistical analysis was performed using SPSS Statistics 17.0 (SPSS, Inc., Chicago, IL, USA), and the comparisons of frequency estimates between groups were performed by χ^2^ testes. The residue alignment was performed by MEGA7.0 software ([www.megasoftware.net](www.megasoftware.net)) ([@b21-mmr-17-05-7027]).

Results
=======

### Summary of BCR/TCR sequencing

For the BCR libraries, 466,667 and 408,506 reads from the IgAN and the control group, respectively, were obtained. Following filtering out of unknown sequences, 462,372 and 402,373 clean immune sequences were identified, of which 349,990 and 321,803 were CDR3 sequences. 34,078 unique CDR3 nucleotide sequences and 24,049 unique CDR3 amino acid clonotypes were detected in the IgAN group, and 38,191 unique CDR3 nucleotide sequences and 26,919 unique CDR3 amino acid clonotypes were detected in the control group. For the TCR libraries, 467,542 and 491,499 reads from the IgAN and the control group, respectively, were obtained. There were 464,053 and 487,974 clean immune sequences, of which 344,679 and 362,658 were CDR3 sequences; and 46,735 unique CDR3 nucleotide sequences and 41,573 unique CDR3 amino acid clonotypes were identified in the IgAN group, and 27,272 unique CDR3 nucleotide sequences and 22,918 unique CDR3 amino acid clonotypes were identified in the control group. The numbers of unique CDR3 nucleotide sequences and unique CDR3 amino acid clonotypes indicated that 29.43 and 11.05% nucleotide sequences would encode identical amino acid clonotypes in the BCR and TCR, respectively.

### Characteristics of the BCR/TCR CDR3 length distribution

The length distribution of the BCR/TCR CDR3 loop is an important index for the determination of B/T cell repertoire diversity. In the present study, the average BCR CDR3 lengths did not differ significantly between the IgAN (17.01±4.27) and the control group (17.25±4.15; P\>0.05). The average TCR CDR3 lengths did not differ significantly between the IgAN (12.56±2.56) and the control group (12.42±2.20; P\>0.05). The length distribution of the BCR/TCR CDR3 loops in the IgAN group and the control group were observed to fit well to a Gaussian distribution curve (R^2^≈1.0; [Fig. 2](#f2-mmr-17-05-7027){ref-type="fig"}). In Gaussian distribution curves, the R^2^ index ranges between 0 and 1, corresponding to worst and best fit.

### BCR/TCR CDR3 with highly expanded clones

The expression level of each unique BCR/TCR CDR3 amino acid sequence was evaluated by the unique BCR/TCR CDR3 DNA sequence frequency following alignment. Highly expanded clones (HECs) were defined as those with a frequency \>0.01% ([@b22-mmr-17-05-7027]). For the BCR CDR3, a total of 3,133 clones were identified as HECs, with a median HEC ratio of 0.0192664% in the IgAN group; whereas, in the control group, 2,338 clones were HECs, with a median HEC ratio of 0.0277151%. A χ^2^ test indicated that there were significantly more BCR CDR3 HECs in the IgAN compared with the control group (P\<0.05; data not shown). The BCR CDR3 HECs in each group were highly diverse, and all of the HECs in the IgAN group were unique clones. For the TCR CDR3, a total of 1,804 clones were identified as HECs, with a median HEC ratio of 0.0133458% in the IgAN group; and in the control group, 2277 clones were identified as HECs, with a median HEC ratio of 0.0228866%. The HECs of the TCR CDR3 in each group were highly diverse, with 98.7804878% of TCR HECs in the IgAN group and 98.3311375% of TCR HECs in the control group observed to be unique clones. Furthermore, when the frequency distribution of the BCR/TCR repertoire was plotted, a great variation between the two groups of samples was identified, and the frequency distribution was markedly more skewed in the IgAN group ([Fig. 3](#f3-mmr-17-05-7027){ref-type="fig"}).

### Conserved BCR/TCR CDR3 in the IgAN and control groups

The public clones in the IgAN and control groups were considered to be an important aspect of the conserved clones; a total of 12 BCR CDR3 clones and 228 TCR CDR3 clones were identified as public ones, of which 22 in the IgAN group were HECs. The χ^2^ test indicated that a total of 16 public clones, including one clone of BCR CDR3 and 15 clones of TCR CDR3, were expressed with a significantly higher frequency in IgAN patients compared with the control group (P\<0.001; [Fig. 4](#f4-mmr-17-05-7027){ref-type="fig"}). In order to identify whether there were any conserved BCR/TCR CDR3 residues among the unique clones, the top 30 highly expressed BCR/TCR CDR3 clones were aligned, and it was demonstrated that the amino acid residues of BCR/TCR CDR3 may not be encoded randomly; there were several conserved BCR/TCR CDR3 residues, including GMDV, EQY and EQF, that were recurrent \>3 times only in the IgAN group ([Fig. 5](#f5-mmr-17-05-7027){ref-type="fig"}).

### VDJ gene recombination of the BCR/TCR CDR3

Diversity of the BCR/TCR CDR3 is generated by the process of VDJ genetic recombination, in which certain genes in the V, D and J gene family are selected. In order to avoid distortion by dominant clones, which may be expanded as a consequence of an immune response, the composition of unique CDR3 sequences was analyzed and their copies disregarded. The composition of the BCR was additionally analyzed by the gene sub-segment usage of IGHV, IGHD, IGHJ; and TCR by the gene sub-segment usage of TRBV, TRBD and TRBJ. The recombination of genes from the V, D and J gene family in the BCR/TCR CDR3 appeared to be conserved, and it was demonstrated that 73 genes in the IGHV subfamily, 30 genes in the IGHD subfamily, six genes in the IGHJ subfamily, 53 genes in the TRBV subfamily, two genes in the TRBD subfamily and 12 genes in the TRBJ subfamily were commonly used in both groups ([Fig. 6](#f6-mmr-17-05-7027){ref-type="fig"}). However, the VDJ recombination of BCR/TCR CDR3 exhibited great variation between the two groups of samples, with the χ^2^ test indicating that four of the seven high frequency VDJ gene recombinations (frequency \>1.0%), including IGHV3-11/IGHD3-10/IGHJ6, IGHV3-30/IGHD3-10/IGHJ6, TRBV6-6/TRBJ2-7/TRBD2 and TRBV12-3/TRBJ1-1/TRBD1, were present with a significantly higher frequency in the IgAN compared with the control group (P\<0.001; data not shown).

Discussion
==========

B and T cells serve important roles in the human immune system, and understanding their receptor characteristics in human autoimmune diseases may help the development of specific immunotherapeutic interventions for diseases in the clinic ([@b23-mmr-17-05-7027]). IgAN is widely defined as a human autoimmune disease, and certain studies have indicated that a cytokine-mediated switch of naive B cells to antibody-secreting cells or Toll-like receptor ligation pathways in T-cells may be important in the pathogenesis of IgAN ([@b6-mmr-17-05-7027],[@b24-mmr-17-05-7027]). In the clinical setting, certain classical immunosuppressive drugs that exhibit pleiotropic effects, including cyclophosphamide and azathioprine, have been used for the treatment of IgAN ([@b25-mmr-17-05-7027],[@b26-mmr-17-05-7027]). With the development of next-generation sequencing, it is possible to analyze the human immune repertoires in different physiological and pathological conditions with a high depth, which was not achievable previously ([@b27-mmr-17-05-7027],[@b28-mmr-17-05-7027]).

In the present study, a large number of BCR/TCR CDR3 sequences at the DNA level were resolved, providing a large quantity of novel information regarding immune repertoires in IgAN. With regard to the common index for the determination of B/T cell repertoire diversity, the length distribution of the BCR/TCR CDR3 loop appeared to fit well to a Gaussian distribution curve in the IgAN and control groups. This indicated that there may be no notable alterations in length distribution compared with certain typical autoimmune disorders ([@b18-mmr-17-05-7027]). As another common index, the HECs of BCRs and TCRs exhibited certain differences; for example, the number of BCR HECs was increased in the IgAN compared with the control group, whereas the TCR HECs did not exhibit the same trend. This result indicated that there were more BCR CDR3 sequences with higher frequencies in the disease condition of IgAN. As IgAN is a disease characterized by mesangial IgA deposits, a higher frequency of BCR HECs may contribute to a higher frequency of class-switching of prime naive B cells to IgA^+^ antibody-secreting cells following mucosal infection ([@b6-mmr-17-05-7027]).

BCR/TCR CDR3 peptides are believed to be among the most complex and diverse amino acid sequences in humans ([@b29-mmr-17-05-7027]). Studies have indicated that BCR/TCR CDR3 is encoded by somatic rearrangement between IGHV/IGHD/IGHJ (TRBV/TRBD/TRBJ) gene segments, and that receptor diversity may be augmented by non-template nucleotide trimming or addition at different gene segment junction sites ([@b30-mmr-17-05-7027],[@b31-mmr-17-05-7027]). Therefore, the original hypervariable sequences of CDR3 may be encoded randomly and are able to recognize millions of antigens ([@b32-mmr-17-05-7027]). Notably, public clones of BCR/TCR CDR3 sequences in the two groups of samples were identified, including 12 BCR and 228 TCR CDR3 clones, certain of which were HECs. Furthermore, certain of the BCR/TCR CDR3 residues appeared to be conserved in different clones. These findings indicated that the BCR/TCR CDR3 may not be produced randomly. Public (conserved) B/T cells are known to be key factors affecting human health ([@b33-mmr-17-05-7027]). Notably, there were public sequences with significantly different frequencies in the IgAN group. It is possible that these public clones or residues with significantly higher frequency may be the initiators of IgAN, and may represent potential targets for immunotherapeutic intervention.

Regarding the use of IGHV/IGHD/IGHJ in encoding the BCR CDR3, there were certain common characteristics in the two groups of samples, including the most highly used gene segment, IGHV3-11/IGHD3-10/IGHJ6; this indicated that gene segment usage of BCR CDR3 may be conserved. Regarding the use of TRBV/TRBD/TRBJ in the TCR CDR3, there were certain common gene combinations in the two groups, while the most highly used gene segment in the IgAN group, TRBV6-6/TRBJ2-7/TRBD2, had a lower frequency in the control group. Although it may be difficult to fully understand the different degrees of BCR/TCR (V/D/J) repertoire usage, fully describing the gene segment usages of BCR/TCR CDR3 may be valuable for understanding the background of IgAN.

In conclusion, the present study attempted to profile the entire B- and T-cell repertoires in patients with IgAN by high-throughput sequencing for the first time, to the best of our knowledge. The global repertoires contain a wealth of conserved characteristics, especially the conserved BCR/TCR CDR3 sequences and the usage of gene segments, which may provide novel information for the treatment of IgAN.
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![Public clones in the two groups of samples. (A) The public BCR CDR3 clones. (B) The public clones of the highly expanded TCR CDR3. \*P\<0.001 vs. control. BCR, B-cell receptors; IgAN, immunoglobulin A nephropathy; TCRs, T-cell receptors; CDR3, complementarity-determining region 3.](MMR-17-05-7027-g03){#f4-mmr-17-05-7027}
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###### 

Clinical data of patients with immunoglobulin A nephropathy.

  Case no.   Age, years   Lee\'s grading   SCR, µmol/l   BUN, mmol/l   Proteinuria, g/24 h   URBC, cells/µl
  ---------- ------------ ---------------- ------------- ------------- --------------------- ----------------
  1          27           III              62            4.10          0.795                 150
  2          44           III              122           7.48          1.148                 250
  3          36           III              70            3.50          0.704                 150
  4          36           III              129           4.35          1.036                 250
  5          26           IV               127           7.67          2.739                 250
  6          34           IV               102           4.30          0.840                 150
  7          31           III              69            3.99          0.730                 250
  8          43           IV               116           5.19          1.872                 150

BUN, blood urea nitrogen; SCR, serum creatinine; URBC, urinary red blood cell.

###### 

Primers for the amplification of BCR CDR3.

  Primer         Forward/reverse   Sequence (5′→3′)
  -------------- ----------------- ------------------------------------------------
  IGHV1-18       Forward           CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATGACCACAGAC
  IGHV1-2/1-46   Forward           CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCAKKACCAGGGAC
  IGHV1-24       Forward           CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATGACCGAGGAC
  IGHV1-3/1-45   Forward           CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATTACYAGGGAC
  IGHV1-69/1-f   Forward           CAGACGTGTGCTCTTCCGATCTAGAGAGTCACGATWACCRCGGAC
  IGHV1-8        Forward           CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATGACCAGGAAC
  IGH2-70/26/5   Forward           CAGACGTGTGCTCTTCCGATCTAGACCAGGCTCACCATYWCCAAGG
  IGHV3          Forward           CAGACGTGTGCTCTTCCGATCTAGGGCCGATTCACCATCTCMAG
  IGH4           Forward           CAGACGTGTGCTCTTCCGATCTAGCGAGTCACCATRTCMGTAGAC
  IGHV5-51       Forward           CAGACGTGTGCTCTTCCGATCTAGCAGCCGACAAGTCCATCAGC
  IGHV6-1        Forward           CAGACGTGTGCTCTTCCGATCTAGAGTCGAATAACCATCAACCCAG
  IGHV7-NEW      Forward           CAGACGTGTGCTCTTCCGATCTAGGACGGTTTGTCTTCTCCTTG
  HIGHJ-Rev1     Reverse           CTACACGACGCTCTTCCGATCTCTGAGGAGACRGTGACCAGGGTG
  HIGHJ-Rev2     Reverse           CTACACGACGCTCTTCCGATCTCTGAAGAGACGGTGACCATTGTC
  HIGHJ-Rev3     Reverse           CTACACGACGCTCTTCCGATCTCTGAGGAGACGGTGACCAGGGT
  HIGHJ-Rev4     Reverse           CTACACGACGCTCTTCCGATCTTGAGGAGACGGTGACCGTGGTC

###### 

Primers for the amplification of TCR CDR3.

  Primer                   Forward/reverse   Sequence (5′→3′)
  ------------------------ ----------------- ------------------------------------------------------------
  TRBV2F-IND               Forward           CAGACGTGTGCTCTTCCGATCTAGATTTCACTCTGAAGATCCGGTCCAC
  TRBV9F-IND               Forward           CAGACGTGTGCTCTTCCGATCTAGCCTGACTTGCACTCTGAACTAAACCT
  TRBV14F-IND              Forward           CAGACGTGTGCTCTTCCGATCTAGGGAGGGACGTATTCTACTCTGAAGG
  TRBV15F-IND              Forward           CAGACGTGTGCTCTTCCGATCTAGTTCTTGACATCCGCTCACCAGG
  TRBV19F-IND              Forward           CAGACGTGTGCTCTTCCGATCTAGTCCTTTCCTCTCACTGTGACATCGG
  TRBV3-1-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGAAACAGTTCCAAATCGMTTCTCAC
  TRBV4-1/2/3-F4-IND       Forward           CAGACGTGTGCTCTTCCGATCTAGCAAGTCGCTTCTCACCTGAATG
  TRBV5-1-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGGCCAGTTCTCTAACTCTCGCTCT
  TRBV5-4/5/6/8-F4-IND     Forward           CAGACGTGTGCTCTTCCGATCTAGTCAGGTCGCCAGTTCCCTAAYTAT
  TRBV6-1/2/3/5/8-F4-IND   Forward           CAGACGTGTGCTCTTCCGATCTAGCAATGGCTACAATGTCTCYAGAT
  TRBV6-4-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGTGATGGTTATAGTGTCTCCAGAG
  TRBV6-9-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGCGATGGCTACAATGTATCCAGAT
  TRBV6-6-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGGAATGGCTACAACGTCTCCAGAT
  TRBV7-2/4/6/7/8-F4-IND   Forward           CAGACGTGTGCTCTTCCGATCTAGGGGATCCGTCTCCACTCTGAMGAT
  TRBV7-3-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGGGGATCCGTCTCTACTCTGAAGAT
  TRBV7-9-F4-IND           Forward           CAGACGTGTGCTCTTCCGATCTAGGGGATCTTTCTCCACCTTGGAGAT
  TRBV10-1-F4-IND          Forward           CAGACGTGTGCTCTTCCGATCTAGCCTCACTCTGGAGTCTGCTGCC
  TRBV10-2/3-F4-IND        Forward           CAGACGTGTGCTCTTCCGATCTAGCCTCACTCTGGAGTCMGCTACC
  TRBV11-1/2/3-F4-IND      Forward           CAGACGTGTGCTCTTCCGATCTAGGCAGAGAGGCTCAAAGGAGTAGACT
  TRBV12-3/4-F4-IND        Forward           CAGACGTGTGCTCTTCCGATCTAGATCGATTCTCAGCTAAGATGCCT
  TRBV12-5-F4-IND          Forward           CAGACGTGTGCTCTTCCGATCTAGATCGATTCTCAGCAGAGATGCCT
  TRBV13-F4-IND            Forward           CAGACGTGTGCTCTTCCGATCTAGTCGATTCTCAGCTCAACAGTTC
  TRBV18-F4-IND            Forward           CAGACGTGTGCTCTTCCGATCTAGTAGATGAGTCAGGAATGCCAAAG
  TRBV20-1-F4-IND          Forward           CAGACGTGTGCTCTTCCGATCTAGAACCATGCAAGCCTGACCTT
  TRBV24-1-F2-IND          Forward           CAGACGTGTGCTCTTCCGATCTAGCTCCCTGTCCCTAGAGTCTGCCAT
  TRBV25-1F-IND            Forward           CAGACGTGTGCTCTTCCGATCTAGGCCCTCACATACCTCTCAGTACCTC
  TRBV27/28-F4-IND         Forward           CAGACGTGTGCTCTTCCGATCTAGGGAGATGTTCCTGARGGGTACA
  TRBV29-1-F4-IND          Forward           CAGACGTGTGCTCTTCCGATCTAGAACTCTGACTGTGAGCAACATGAG
  TRBV16-F2-IND            Forward           CAGACGTGTGCTCTTCCGATCTAGCTGTAGCCTTGAGATCCAGGCTACGA
  TRBV30-F5-IND            Forward           CAGACGTGTGCTCTTCCGATCTAGCAGATCAGCTCTGAGGTGCCCCA
  TRBJ1.1-R2-P1            Reverse           CTACACGACGCTCTTCCGATCTCTTACCTACAACTGTGAGTCTGGTG
  TRBJ1.2R-P1              Reverse           CTACACGACGCTCTTCCGATCTCTTACCTACAACGGTTAACCTGGTC
  TRBJ1.3R-P1              Reverse           CTACACGACGCTCTTCCGATCTCTTACCTACAACAGTGAGCCAACTT
  TRBJ1.4R-P1              Reverse           CTACACGACGCTCTTCCGATCTCATACCCAAGACAGAGAGCTGGGTTC
  TRBJ1.5R-P1              Reverse           CTACACGACGCTCTTCCGATCTCTTACCTAGGATGGAGAGTCGAGTC
  TRBJ1.6R-P1              Reverse           CTACACGACGCTCTTCCGATCTCATACCTGTCACAGTGAGCCTG
  TRBJ2.1R-P1              Reverse           CTACACGACGCTCTTCCGATCTCCTTCTTACCTAGCACGGTGA
  TRBJ2.2R-P1              Reverse           CTACACGACGCTCTTCCGATCTCTTACCCAGTACGGTCAGCCT
  TRBJ2.3R-P1              Reverse           CTACACGACGCTCTTCCGATCTCCGCTTACCGAGCACTGTCAG
  TRBJ2.4R-P1              Reverse           CTACACGACGCTCTTCCGATCTCCAGCTTACCCAGCACTGAGA
  TRBJ2.5-R2-P1            Reverse           CTACACGACGCTCTTCCGATCTCGAGCACCAGGAGCCGCGT
  TRBJ2.6R-P1              Reverse           CTACACGACGCTCTTCCGATCTCTCGCCCAGCACGGTCAGCCT
  TRBJ2.7-R2-P1            Reverse           CTACACGACGCTCTTCCGATCTCTTACCTGTGACCGTGAGCCTG
  P1                       Reverse           AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT
